Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2018 Filed Jan 23, 2018 01:43 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 20,000 | $48.04 | $960,716.00 |
DisclosureSEC source: 0001104659-18-003366 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.900 to $48.325, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 22, 2018 Filed Jan 23, 2018 01:43 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-003366 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · derivative · entry 6 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,250 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · derivative · entry 5 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
SaleCommon Stock | 15,000 | $47.03 | $705,499.50 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 4 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.10, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionCommon Stock | 15,000 | $9.24 | $138,600.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
SaleCommon Stock | 9,250 | $45.00 | $416,250.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionCommon Stock | 9,250 | $7.90 | $73,075.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 20,000 | $44.98 | $899,500.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.00, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:38 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-002700 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 5,750 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC |
Vaughn VictorSr. VP of Sales
|
SaleCommon Stock | 5,750 | $45.03 | $258,927.68 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.45, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionCommon Stock | 5,750 | $7.90 | $45,425.00 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 7 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 6 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · derivative · entry 5 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 50,000 | $43.56 | $2,178,145.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 4 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,975 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.2500 to $43.8500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 30,000 | $9.24 | $277,200.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $7.90 | $158,000.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 16:32 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 25,000 | $5.88 | $147,000.00 |
DisclosureSEC source: 0001104659-18-002075 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 12, 2017. F2 · balance_after: Includes an aggregate of 259 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC |
Vaughn VictorSr. VP of Sales
|
SaleCommon Stock | 15,000 | $42.04 | $630,649.50 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0000 to $42.4000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionCommon Stock | 15,000 | $7.90 | $118,500.00 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 55,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC |
Vaughn VictorSr. VP of Sales
|
SaleCommon Stock | 55,000 | $40.11 | $2,206,308.50 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.0000 to $40.7000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC |
Vaughn VictorSr. VP of Sales
|
Exercise / conversionCommon Stock | 55,000 | $7.90 | $434,500.00 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · balance_after: Includes an aggregate of 785 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 23:13 UTC |
Khattar Jack A.Director · President, CEO
|
GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,500 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 23:13 UTC |
Khattar Jack A.Director · President, CEO
|
GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,654 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 23:13 UTC |
Khattar Jack A.Director · President, CEO
|
GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,904 F3 · kind: This transaction involved a gift of securities by the Reporting Person to another daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 23:13 UTC |
Khattar Jack A.Director · President, CEO
|
GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,154 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. F2 · balance_after: Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 11 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 23,481 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 10 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 23,481 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $5.88 | $88,200.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 7 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 23,481 | $48.89 | $1,147,964.96 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 6 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.6000 to $49.3500, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 23,481 | $7.90 | $185,499.90 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 5 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 23:22 UTC |
Bhatt Padmanabh P.Sr VP of IP, CSO
|
SaleCommon Stock | 5,000 | $49.86 | $249,302.50 |
DisclosureSEC source: 0001104659-17-056609 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.8500 to $49.9000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 9 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F6 · derivative.exercise_date: The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,519 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · derivative · entry 8 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,481 Underlying: Common Stock · 26,519 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $5.88 | $88,200.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 4 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 1,519 | $48.00 | $72,912.00 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 3 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
SaleCommon Stock | 25,000 | $46.36 | $1,158,902.50 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 2 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.0000 to $47.3500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 19:23 UTC |
PATRICK GREGORY SVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 26,519 | $7.90 | $209,500.10 |
DisclosureSEC source: 0001104659-17-056611 · a4.xml · nonDerivative · entry 1 PATRICK GREGORY S · CIK 0001219844 · VP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F2 · balance_after: Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 23:22 UTC |
Schwabe Stefan K.F.Executive Vice President R&D
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001104659-17-056610 · a4.xml · derivative · entry 3 Schwabe Stefan K.F. · CIK 0001557657 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2022-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on August 9, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 23:22 UTC |
Schwabe Stefan K.F.Executive Vice President R&D
|
SaleCommon Stock | 95,000 | $46.59 | $4,425,575.00 |
DisclosureSEC source: 0001104659-17-056610 · a4.xml · nonDerivative · entry 2 Schwabe Stefan K.F. · CIK 0001557657 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.000 to $47.800, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 23:22 UTC |
Schwabe Stefan K.F.Executive Vice President R&D
|
Exercise / conversionCommon Stock | 95,000 | $12.92 | $1,227,400.00 |
DisclosureSEC source: 0001104659-17-056610 · a4.xml · nonDerivative · entry 1 Schwabe Stefan K.F. · CIK 0001557657 · Executive Vice President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017. F2 · balance_after: Includes an aggregate of 324 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 00:32 UTC |
Bhatt Padmanabh P.Sr.VP of IP, CSO
|
SaleCommon Stock | 3,709 | $45.23 | $167,754.73 |
DisclosureSEC source: 0001104659-17-052304 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr.VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.0750 to $45.4750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 20:24 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 3,735 | $44.90 | $167,701.50 |
DisclosureSEC source: 0001104659-17-045053 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,209 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 20:26 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 2,556 | $44.90 | $114,774.37 |
DisclosureSEC source: 0001104659-17-041823 · a4.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,944 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 24, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.900 to $44.925, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:42 UTC |
NEWHALL CHARLES W IIIDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039592 · a4.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.